Back to top
more

Precision BioSciences, Inc. (DTIL)

(Delayed Data from NSDQ)

$11.51 USD

11.51
434,980

-0.23 (-1.96%)

Updated Nov 25, 2020 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.33%
2Buy17.77%
3Hold9.37%
4Sell4.88%
5Strong Sell1.79%
S&P50010.56%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 20% (202 out of 254)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Balance Sheet

Research for DTIL

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Precision BioSciences, Inc. falls in the month of December.

All items in Millions except Per Share data.

12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Assets          
Cash & Equivalents 181 103 63 NA NA
Receivables 1 1 0 NA NA
Notes Receivable 0 0 0 NA NA
Inventories 0 0 0 NA NA
Other Current Assets 12 12 2 NA NA
Total Current Assets 194 116 64 NA NA
Net Property & Equipment 40 21 8 NA NA
Investments & Advances 0 0 0 NA NA
Other Non-Current Assets 0 0 0 NA NA
Deferred Charges 0 0 0 NA NA
Intangibles 1 1 0 NA NA
Deposits & Other Assets 1 0 0 NA NA
Total Assets 235 139 73 NA NA
Liabilities & Shareholders Equity 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Notes Payable 0 0 0 NA NA
Accounts Payable 2 2 2 NA NA
Current Portion Long-Term Debt 0 0 0 NA NA
Current Portion Capital Leases 0 0 0 NA NA
Accrued Expenses 8 3 2 NA NA
Income Taxes Payable 0 0 0 NA NA
Other Current Liabilities 16 8 6 NA NA
Total Current Liabilities 27 14 9 NA NA
Mortgages 0 0 0 NA NA
Deferred Taxes/Income 66 83 89 NA NA
Convertible Debt 0 0 0 NA NA
Long-Term Debt 0 0 0 NA NA
Non-Current Capital Leases 0 0 0 NA NA
Other Non-Current Liabilities 4 2 1 NA NA
Minority Interest (Liabilities) 0 0 0 NA NA
Total Liabilities 97 99 99 NA NA
Shareholders Equity 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Preferred Stock 0 0 0 NA NA
Common Stock (Par) 0 0 0 NA NA
Capital Surplus 316 126 14 NA NA
Retained Earnings -177 -85 -39 NA NA
Other Equity 0 0 0 NA NA
Treasury Stock 1 1 1 NA NA
Total Shareholder's Equity 138 40 -26 NA NA
Total Liabilities & Shareholder's Equity 235 139 73 NA NA
Total Common Equity 138 40 -26 0 0
Shares Outstanding 50.70 NA NA NA NA
Book Value Per Share 2.73 0.00 0.00 0.00 0.00

Fiscal Year End for Precision BioSciences, Inc. falls in the month of December.

All items in Millions except Per Share data.

9/30/2020 6/30/2020 3/31/2020 12/31/2019 9/30/2019
Assets          
Cash & Equivalents 104 127 154 181 206
Receivables 10 0 4 1 0
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 8 10 9 12 13
Total Current Assets 123 137 167 194 220
Net Property & Equipment 36 38 39 40 39
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 1 1 1 1 1
Deposits & Other Assets 2 1 1 1 0
Total Assets 169 184 214 235 260
Liabilities & Shareholders Equity 9/30/2020 6/30/2020 3/31/2020 12/31/2019 9/30/2019
Notes Payable 0 0 0 0 0
Accounts Payable 1 2 2 2 4
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 10 8 7 8 8
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 29 23 13 16 11
Total Current Liabilities 42 34 24 27 24
Mortgages 0 0 0 0 0
Deferred Taxes/Income 54 55 66 66 78
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 4 3
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 105 99 99 97 105
Shareholders Equity 9/30/2020 6/30/2020 3/31/2020 12/31/2019 9/30/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 327 323 320 316 313
Retained Earnings -263 -237 -204 -177 -156
Other Equity 0 0 0 0 0
Treasury Stock 1 1 1 1 1
Total Shareholder's Equity 64 86 115 138 156
Total Liabilities & Shareholder's Equity 169 184 214 235 260
Total Common Equity 64 86 115 138 156
Shares Outstanding 52.30 51.80 51.40 50.70 50.60
Book Value Per Share 1.22 1.65 2.24 2.73 3.08